Lupin SWOT Analysis, Competitors, STP & USP

Lupin

Pharmaceutical

Pharma and Healthcare

Being lupin, enriching lives everyday

Lupin is the world’s largest manufacturer of anti- tuberculosis drugs

Anti TB segment, Cardiovascular, Oral and injectable, pediatric products API’s, Anti-Infectives segment

Healthcare professionals, doctors treating patients suffering from TB, respiratory  &  cardiovascular diseases

It is innovation led pharmaceutical company, which specializes in generic, API & branded formulations for developed & developing world.

Below are the Strengths in the SWOT Analysis of Lupin:

1. World wide leader in Cephalosporin and Anti TB drugs
2. Considerable presence in market for drugs against Asthma, Pediatrics, Diabetes, and CNS boosts the sales
3. In the US and Japanese market it is the largest generic player
4. Acquisition of I’rom pharma helped to increase its product list and in turn sales

5. Wide global footprint as it is present in over 70 countries

Here are the weaknesses in the Lupin SWOT Analysis:

1.High dependence on global formulation business with 84% revenue coming from US market
3. Forecasting done on technological level is less

4. It operates in low growth segments such CNS, respiratory diseases

Following are the Opportunities in Lupin SWOT Analysis:

1.Increased health awareness

2. Emerging technological trends in drug delivery

3. Increasing prevalence of TB in developing countries

The threats in the SWOT Analysis of Lupin are as mentioned:

1.Unsuccessful  assimilation of questions

2.Rigid opposition both from locals and global company

3. Soaring cost of discovering novel products

Below are the top 4 Lupin competitors:

1. Sun pharmaceuticals

2. Ranbaxy

3. Dr. Reddy’s lab

4. Cipla